Skip to main content
Rossana C.N. Melo on Muck Rack

Rossana C.N. Melo

As seen in: ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rossana C.N.

Contact Rossana C.N., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)

|
By Rossana C.N. Melo, Marc E. Rothenberg, Vijaya Knight, Lusia Sepiashvili
| ScienceDirect Verified
Pivotal studies with dupilumab demonstrated clinically relevant improvements in nasal polyp score, symptom score, and quality-of-life score in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). We evaluated the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 European tertiary-care centers.
Open in Who Shared Issue with article?

The rs6967330 minor allele in CDHR3 is a significant risk factor for severe acute exacerbations in chronic rhinosinusitis

|
By Sijia Wang, Raymond Cho, Marc E. Rothenberg, Rossana C.N. Melo
| ScienceDirect Verified
This study was supported by grants from the (grant no. R01AI146131 to F.D.M. and E.H.C. and grant nos. R21 AI176305-01A1 and R01AI099108-11A1 to A.B.). Disclosure of potential conflict of interest: E. H. Chang is an advisor for Sanofi/Regeneron. A. Bosco is a cofounder, equity holder, and director of the startup company Respiradigm Pty Ltd and the subsidiary First Breath Health Pty Ltd, which are related to this work; and is the founder of the startup company
Open in Who Shared Issue with article?
See all 2 articles